Comorbidity of inflammatory bowel diseases and psoriasis

Inflammatory bowel diseases, which include Crohn's disease and ulcerative colitis, are a global disease of the 21st century. Psoriasis affects about 125 million people worldwide, it is one of the most common skin diseases and occurs in 2–3 % of the population of countries. Psoriasis, psoriatic arthritis are extraintestinal (systemic) manifestations of IBD, not associated with the activity of ulcerative colitis and Crohn's disease. At the same time, the epidemiology of the relationship between IBD and psoriasis has not been sufficiently studied. We searched the Pubmed and Scopus databases for articles published before 01/25/2025 that examined the relationship between IBD and psoriasis. The results of epidemiological and clinical studies, their generalizations in systematic reviews and meta-analyses, indicate the presence of a bidirectional relationship between IBD and psoriasis. The mechanisms of the relationship include similar pathophysiological processes, including comparable immunopathogenic mechanisms (primarily the involvement of Th17, IL-17, IL-23 and TNF-α), common inflammatory pathways, common susceptibility loci and DNA polymorphism at the genetic level, dysbiosis of the intestinal microbiome, intestinal permeability disorders, which play a key role in the development of IBD and psoriasis. In patients with psoriasis, consultation with a gastroenterologist is indicated in the presence of intestinal symptoms. When curating patients with IBD and psoriasis, interaction and close cooperation between a gastroenterologist and a dermatologist is advisable.

1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.Lancet. 2017 Dec 23; 390 (10114): 2769–2778. DOI: 10.1016/S01406736(17)32448-0

2. Tarasova L.V., Trukhan D.I. Bolezni kishechnika. Klinika, diagnostika i lechenie. SPb.: SpeczLit, 2022. 222 s. (In Russ.). URL: https://elibrary.ru/item.asp?id=49497776

3. Klinicheskie rekomendacii Yazvenny`j kolit. 2024. Odobreno Nauchno-prakticheskim Sovetom Minzdrava RF. (In Russ.). URL: https://cr.minzdrav.gov.ru/recomend/193_2

4. Klinicheskie rekomendacii Bolezn` Krona. 2024. Odobreno Nauchno-prakticheskim Sovetom Minzdrava RF (In Russ.)URL: https://cr.minzdrav.gov.ru/preview-cr/176_2

5. Tarasova L.V., Trukhan D.I. Bolezni kishechnika. Klinika, diagnostika i lechenie. SPb.: SpeczLit; 2013. 144 s. (In Russ.) URL: https://www.razym.ru/nauchmed/vnutri/321103-truhan-d-bolezni-kishechnika-klinika diagnostika-i-lechenie-uchebnoe-posobie.html

6. Klinicheskie rekomendacii Psoriaz. 2023. Odobreno Nauchno-prakticheskim Sovetom Minzdrava RF. (In Russ.). URL: https://cr.minzdrav.gov.ru/preview-cr/234_2

7. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, et al. Psoriasis and comorbid diseases: Epidemiology.J Am Acad Dermatol. 2017 Mar; 76 (3): 377–390. DOI: 10.1016/j.jaad.2016.07.064

8. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019 Sep 5; 20 (18): 4347. DOI: 10.3390/ijms20184347

9. Yamazaki F. Psoriasis: Comorbidities. J Dermatol. 2021 Jun; 48 (6): 732–740. DOI: 10.1111/1346-8138.15840

10. Shani U, Ben-Shabat N, Qassem R, Lahat A, Omar M, et al. The association between psoriasis, psoriasis severity, and inflammatory bowel disease: a population-based analysis. Therap Adv Gastroenterol. 2024 Jan 27; 17: 17562848241227037. DOI: 10.1177/17562848241227037

11. Moon JM, Lee JY, Koh SJ, Park H, Kang S. et al. Incidence of Psoriasis in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Matched Cohort Study. Dermatology. 2021; 237 (3): 330–337. DOI: 10.1159/000514030

12. Eppinga H, Poortinga S, Thio HB, Nijsten TEC, Nuij VJAA. et al. Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease.Inflamm Bowel Dis. 2017 Oct; 23 (10): 1783–1789. DOI: 10.1097/MIB.0000000000001169.

13. Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study.J Invest Dermatol. 2019 Feb; 139 (2): 316–323. doi: 10.1016/j.jid.2018.07.029

14. Lee JY, Kang S, Bae JM, Jo SJ, Koh SJ, Park HS. Psoriasis increases the risk of concurrent inflammatory bowel disease: A population-based nationwide study in Korea. Indian J Dermatol Venereol Leprol. 2019 Mar-Apr; 85 (2): 145–152. DOI: 10.4103/ijdvl.IJDVL_875_17

15. Ding RL, Zheng Y, Bu J. Exploration of the biomarkers of comorbidity of psoriasis with inflammatory bowel disease and their association with immune infiltration. Skin Res Technol. 2023 Dec; 29 (12): e13536. DOI: 10.1111/srt.13536

16. Fu Y, Lee CH, Chi CC. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018 Dec 1; 154 (12): 1417–1423. DOI: 10.1001/jamadermatol.2018.3631

17. Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease-A Systematic Review and Meta-analysis.J Crohns Colitis. 2020 Mar 13; 14 (3): 351–360. DOI: 10.1093/ecco-jcc/jjz152

18. Sun Y, Li Y, Zhang J. The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases. Sci Rep. 2022 Nov 28;12 (1): 20526. DOI: 10.1038/s41598-022-24872-5

19. Li Y, Guo J, Cao Z, Wu J. Causal Association Between Inflammatory Bowel Disease and Psoriasis: A Two-Sample Bidirectional Mendelian Randomization Study.Front Immunol. 2022 Jun 10; 13: 916645. DOI: 10.3389/fimmu.2022.916645

20. Cai Y, Xie S, Jia X, Chen D, Wu D, et al. Integrated analysis of Mendelian Randomization and Bayesian colocalization reveals bidirectional causal association between inflammatory bowel disease and psoriasis. Ann Med. 2023; 55 (2): 2281658. DOI: 10.1080/07853890.2023.2281658

21. Jauregui W, Abarca YA, Ahmadi Y, Menon VB, Zumárraga DA, et al. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection. Cureus. 2024 Sep 3; 16 (9): e68569. DOI: 10.7759/cureus.68569

22. Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013; 2013: 983902. DOI: 10.1155/2013/983902

23. Tabbarah S, Sulaiman H, Ansah Owusu F, Rajeev Joshi M, Marepalli NR, et al. Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection. Cureus. 2024 Sep 25; 16 (9): e70148. DOI: 10.7759/cureus.70148

24. Vlachos C, Gaitanis G, Katsanos KH, Christodoulou DK, Tsianos E, Bassukas ID. Psoriasis and inflammatory bowel disease: links and risks.Psoriasis (Auckl). 2016 Jul 20; 6: 73–92. DOI: 10.2147/PTT.S85194

25. Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach.J Intern Med. 2021 Aug; 290 (2): 257–278. DOI: 10.1111/joim.13282

26. Simanenkov VI, Maev IV, Tkacheva ON, Alekseenko SA, Andreev DN, et al. Epithelial protective therapy in comorbid diseases. Practical Guidelines for Physicians. Terapevticheskii Arkhiv (Ter. Arkh.). 2022; 94 (8): 6–22. (In Russ.) DOI: 10.26442/00403660.2022.08.201523

27. Trukhan D. I. Syndrome of increased epithelial permeability: answers to frequently asked questions. Clinical review for general practice. 2024; 5 (1): 20–22 (In Russ.). DOI: 10.47407/kr2023.5.1.00354

28. Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Comorbidity of inflammatory bowel diseases and periodontal pathology. Meditsinskiy Sovet. 2024; 18 (15): 215–223. (In Russ.) https://doi.org/10.21518/ms2024–373

29. Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Frątczak A, Kiss N. Psoriasis and Gut Microbiome-Current State of Art. Int J Mol Sci. 2021 Apr 26; 22 (9): 4529. DOI: 10.3390/ijms22094529

30. Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Dig Dis. 2019; 37 (6): 451–457. DOI: 10.1159/000500116

31. Trukhan DI. Tofacitinib in the treatment of ulceral colitis: real-world clinical practice and prospects. Meditsinskiy Sovet. 2024; 18 (15): 200–208. (In Russ.) https://doi.org/10.21518/ms2024–344

32. Sánchez-Martínez MA, Garcia-Planella E, Laiz A, Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermosifiliogr. 2017 Apr; 108 (3): 184–191. DOI: 10.1016/j.ad.2016.07.007

33. Abdelghaffar M, Kottilil S, Murphy MJ, Cohen JM, Damsky W. Paradoxical Psoriasis. Dermatol Clin. 2024 Jul; 42 (3): 471–480. DOI: 10.1016/j.det.2024.02.011

34. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010 Dec; 40 (3): 233–40. DOI: 10.1016/j.semarthrit.2010.04.003

35. Peer FC, Miller A, Pavli P, Subramaniam K. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients. Intern Med J. 2017 Dec; 47 (12): 1445–1448. DOI: 10.1111/imj.13637

36. Townsend CM, Lovegrove F, Khanna R, Wilson AS. Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022 Jun; 55 (11): 1379–1388. DOI: 10.1111/apt.16883

37. Nidegger A, Mylonas A, Conrad C. Paradoxical psoriasis induced by anti-TNF – a clinical challenge. Rev Med Suisse. 2019 Mar 27; 15 (644): 668–671. https://pubmed.ncbi.nlm.nih.gov/30916904/

38. Xie W, Xiao S, Huang H, Zhang Z. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis. Front Immunol. 2022 Mar 1; 13: 847160. DOI: 10.3389/fimmu.2022.847160